Quantifying the effects of antiangiogenic and chemotherapy drug combinations on drug delivery and treatment efficacy.
Open accessThe DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Abstract
Tumor-induced angiogenesis leads to the development of leaky tumor vessels devoid of structural and morphological integrity.Due to angiogenesis, elevated interstitial fluid pressure (IFP) and low blood perfusion emerge as common properties of the tumor microenvironment that act as barriers for drug delivery.In order to overcome these barriers, normalization of vasculature is considered to be a viable option.However, insight is needed into the phenomenon of normalization and in which conditions it can realize its promise.In order to explore the effect of microenvironmental conditions and drug scheduling on normalization benefit, we build a mathematical model that incorporates tumor growth, angiogenesis and IFP.We administer various theoretical combinations of antiangiogenic agents and cytotoxic nanoparticles through heterogeneous vasculature that displays a similar morphology to tumor vasculature.We observe differences in drug extravasation that depend on the scheduling of combined therapy; for concurrent therapy, total drug extravasation is increased but in adjuvant therapy, drugs can penetrate into deeper regions of tumor. Author summaryTumor vessels being very different from their normal counterparts are leaky and lack organization that sustains blood circulation.As a result, insufficient blood supply and high fluid pressure begin to appear inside the tumor which leads to a reduced delivery of drugs within the tumor, especially in tumor center.A treatment strategy that utilizes antivascular drugs is observed to revert these alterations in tumor vessels, making them more normal.This approach is suggested to improve drug delivery by enhancing physical transport of drugs.In this paper, we build a mathematical model to simulate tumor and vessel growth as well as fluid pressure inside the tumor.This framework enables us to simulate drug treatment scenarios on tumors.We use this model to find whether the delivery of the chemotherapy drugs is enhanced by application of anti-vascular drugs by making vessels more normal.Our simulations show that anti-vascular drug not only enhances the
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Antiangiogenic agents are thought to normalize tumor vasculature to allow for better delivery of chemotherapy.”
From Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma (2024) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., & Bergsland, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,716
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Carmeliet, P., & Jain, R. K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3455 · Cited by 1,675
Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5466 · Cited by 1,505
Gabizón, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., & Barenholz, Y. (1994) · PubMed · Cited by 1,382
Determinants of tumor blood flow: a review.
Jain, R. K. (1988) · PubMed · Cited by 1,379
Transport of molecules in the tumor interstitium: a review.
Jain, R. K. (1987) · PubMed · Cited by 1,378
Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248
Tong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., & Jain, R. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0074 · Cited by 1,189
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
Winkler, F., Kozin, S. V., Tong, R. T., Chae, S.-S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.011 · Cited by 1,170
Chauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.45 · Cited by 1,101
Barriers to Drug Delivery in Solid Tumors
Jain, R. K. (1994) · Scientific American · doi:10.1038/scientificamerican0794-58 · Cited by 1,069
Robert, N. J., Diéras, V., Glaspy, J., Brufsky, A. M., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y. T., Zhou, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0982 · Cited by 1,064
Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system
Sengupta, S., Eavarone, D., Capila, I., Zhao, G., Watson, N., Kiziltepe, T., & Sasisekharan, R. (2005) · Nature · doi:10.1038/nature03794 · Cited by 945
Miles, D. W., Chan, A., Dirix, L. Y., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J. H., Provencher, L., Puglisi, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6457 · Cited by 897
(1990) · PubMed · Cited by 757
Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization
Fukumura, D., & Jain, R. K. (2007) · Microvascular Research · doi:10.1016/j.mvr.2007.05.003 · Cited by 691
Repopulation of cancer cells during therapy: an important cause of treatment failure
Kim, J. J., & Tannock, I. F. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1650 · Cited by 686
Jain, R. K., Tong, R. T., & Munn, L. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4102 · Cited by 612
Pluen, A., Boucher, Y., Ramanujan, S., McKee, T. D., Gohongi, T., di Tomaso, E., Brown, E. B., Izumi, Y., Campbell, R. B., Berk, D. A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081626898 · Cited by 603
Delivery of Molecular and Nanoscale Medicine to Tumors: Transport Barriers and Strategies
Chauhan, V. P., Stylianopoulos, T., Boucher, Y., & Jain, R. K. (2011) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-061010-114300 · Cited by 597
Boucher, Y., & Jain, R. K. (1992) · PubMed · Cited by 510
Combining two strategies to improve perfusion and drug delivery in solid tumors
Stylianopoulos, T., & Jain, R. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318415110 · Cited by 508
Stylianopoulos, T., Martin, J. D., Snuderl, M., Mpekris, F., Jain, S. R., & Jain, R. K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4521 · Cited by 477
(2000) · PubMed · Cited by 475
Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer Tumors
Laginha, K. M., Verwoert, S., Charrois, G. J. R., & Allen, T. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0343 · Cited by 441
Tebbutt, N. C., Wilson, K., Gebski, V. J., Cummins, M. M., Zannino, D., van Hazel, G. A., Robinson, B., Broad, A., Ganju, V., Ackland, S. P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.7723 · Cited by 413
McDougall, S. R., Anderson, A. R. A., & Chaplain, M. A. J. (2006) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2005.12.022 · Cited by 383
Combination of antiangiogenesis with chemotherapy for more effective cancer treatment
Ma, J., & Waxman, D. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0715 · Cited by 370
Wu, N. Z., Da, D., Rudoll, T. L., Needham, D., Whorton, A. R., & Dewhirst, M. W. (1993) · PubMed · Cited by 364
Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.
Goel, S., Wong, A. H.-K., & Jain, R. K. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006486 · Cited by 352
Liu, J., Liao, S., Diop-Frimpong, B., Chen, W., Goel, S., Naxerova, K., Ancukiewicz, M., Boucher, Y., Jain, R. K., & Xu, L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117610109 · Cited by 330
Gray, R., Bhattacharya, S., Bowden, C., Miller, K., & Comis, R. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6630 · Cited by 294
McDougall, S. (2002) · Bulletin of Mathematical Biology · doi:10.1006/bulm.2002.0293 · Cited by 291
Netti, P. A., Baxter, L. T., Boucher, Y., Skalak, R., & Jain, R. K. (1995) · PubMed · Cited by 263
Wu, M., Frieboes, H. B., McDougall, S. R., Chaplain, M. A. J., Cristini, V., & Lowengrub, J. (2013) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2012.11.031 · Cited by 229
Seynhaeve, A. L. B., Hoving, S., Schipper, D., Vermeulen, C. E., aan de Wiel-Ambagtsheer, G., van Tiel, S. T., Eggermont, A. M. M., & ten Hagen, T. L. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1599 · Cited by 173
Numerical modeling of drug delivery in a dynamic solid tumor microvasculature
Sefidgar, M., Soltani, M., Raahemifar, K., Sadeghi, M., Bazmara, H., Bazargan, M., & Mousavi Naeenian, M. (2015) · Microvascular Research · doi:10.1016/j.mvr.2015.02.007 · Cited by 162
Stéphanou, A., McDougall, S. R., Anderson, A. R. A., & Chaplain, M. A. J. (2005) · Mathematical and Computer Modelling · doi:10.1016/j.mcm.2005.05.008 · Cited by 160
Interstitial Fluid Flow and Drug Delivery in Vascularized Tumors: A Computational Model
Welter, M., & Rieger, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070395 · Cited by 158
On optimal delivery of combination therapy for tumors
d’Onofrio, A., Ledzewicz, U., Maurer, H., & Schättler, H. (2009) · Mathematical Biosciences · doi:10.1016/j.mbs.2009.08.004 · Cited by 154
Interstitial Fluid Pressure in Tumors: Therapeutic Barrier and Biomarker of Angiogenesis
Lunt, S. J., Fyles, A., Hill, R. P., & Milosevic, M. (2008) · Future Oncology · doi:10.2217/14796694.4.6.793 · Cited by 145
Reddy, S. T., Berk, D. A., Jain, R. K., & Swartz, M. A. (2006) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00389.2006 · Cited by 145
In Vivo Distribution of Polymeric Nanoparticles at the Whole-Body, Tumor, and Cellular Levels
Lee, H., Hoang, B., Fonge, H., Reilly, R. M., & Allen, C. J. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0068-z · Cited by 138
Soltani, M., & Chen, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067025 · Cited by 133
Lack of lymphangiogenesis during breast carcinogenesis
Vleugel, M. M., Bos, R., van der Groep, P., Greijer, A. E., Shvarts, A., Stel, H. V., van der Wall, E., & van Diest, P. J. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.014480 · Cited by 113
Wu, M., Frieboes, H. B., Chaplain, M. A. J., McDougall, S. R., Cristini, V., & Lowengrub, J. S. (2014) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2014.04.012 · Cited by 111
Benefits of Vascular Normalization Are Dose and Time Dependent—Letter
Huang, Y., Stylianopoulos, T., Duda, D. G., Fukumura, D., & Jain, R. K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1989 · Cited by 110
Effect of Pazopanib on Tumor Microenvironment and Liposome Delivery
Tailor, T. D., Hanna, G., Yarmolenko, P. S., Dreher, M. R., Betof, A. S., Nixon, A. B., Spasojevic, I., & Dewhirst, M. W. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0856 · Cited by 106
Ekdawi, S. N., Stewart, J., Dunne, M., Stapleton, S., Mitsakakis, N., Dou, Y. N., Jaffray, D. A., & Allen, C. J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.04.006 · Cited by 102
Theek, B., Gremse, F., Kunjachan, S., Fokong, S., Pola, R., Pechar, M., Deckers, R., Storm, G., Ehling, J., Kiessling, F., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.007 · Cited by 102
Simulation of the Delivery of Doxorubicin to Hepatoma
Goh, Y. F., Kong, H. L., & Wang, C. (2001) · Pharmaceutical Research · doi:10.1023/a:1011076110317 · Cited by 93
Optimal and suboptimal protocols for a class of mathematical models of tumor anti-angiogenesis
Ledzewicz, U., & Schättler, H. (2008) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2008.02.014 · Cited by 92
Patel, K. J., Trédan, O., & Tannock, I. F. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2176-z · Cited by 86
Pinho, S. T. R., Bacelar, F. S., Andrade, R. F. S., & Freedman, H. I. (2012) · Nonlinear Analysis Real World Applications · doi:10.1016/j.nonrwa.2012.07.034 · Cited by 85
Dynamics of tumor growth and combination of anti-angiogenic and cytotoxic therapies
Kohandel, M., Mehran Kardar, A., Milosevic, M., & Sivaloganathan, S. (2007) · Physics in Medicine and Biology · doi:10.1088/0031-9155/52/13/001 · Cited by 82
Self-citationKarathanasis, E., Chan, L., Karumbaiah, L., McNeeley, K., D'Orsi, C. J., Annapragada, A. V., Sechopoulos, I., & Bellamkonda, R. V. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005843 · Cited by 74
Stapleton, S., Milosevic, M., Tannock, I. F., Allen, C. J., & Jaffray, D. A. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.06.008 · Cited by 73
Wu, J., Long, Q., Xu, S., & Padhani, A. R. (2009) · Journal of Biomechanics · doi:10.1016/j.jbiomech.2009.01.009 · Cited by 72
Rygh, C. B., Qin, S., Seo, J. W., Mahakian, L. M., Zhang, H., Adamson, R. H., Chen, J. Q., Borowsky, A. D., Cardiff, R. D., Reed, R. K., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2049 · Cited by 40
Benzekry, S., Chapuisat, G., Ciccolini, J., Erlinger, A., & Hubert, F. (2011) · Comptes Rendus Mathématique · doi:10.1016/j.crma.2011.11.019 · Cited by 39
Davis, D. W., Herbst, R. S., & Abbruzzese, J. L. (2007) · CRC Press eBooks · doi:10.1201/9781420004298 · Cited by 38
Graff, B. A., Kvinnsland, Y., Skretting, A., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600680 · Cited by 27
A theoretical study of the response of vascular tumours to different types of chemotherapy
Panovska‐Griffiths, J., Byrne, H. M., & Maini, P. K. (2007) · Mathematical and Computer Modelling · doi:10.1016/j.mcm.2007.02.028 · Cited by 25
Influence of vascular normalization on interstitial flow and delivery of liposomes in tumors
Ozturk, D., Yonucu, S., Yιlmaz, D., & Ünlü, M. B. (2015) · Physics in Medicine and Biology · doi:10.1088/0031-9155/60/4/1477 · Cited by 18
Self-citationMaxwell, P. H., & Ashcroft, M. A. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605032 · Cited by 14
Research works printed but not linked: 1
- F Curry, 1984, Mechanics and thermodynamics of transcapillary exchange, Handbook of physiology, 4, 309
Cited by
Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment
Teleanu, R. I., Chircov, C., Grumezescu, A. M., & Teleanu, D. M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010084 · Cited by 503
In silico clinical trials: concepts and early adoptions
Pappalardo, F., Russo, G., Tshinanu, F. M., & Viceconti, M. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bby043 · Cited by 279
Gaspar, N., Venkatramani, R., Hecker-Nolting, S., Melcon, S. G., Locatelli, F., Bautista, F., Longhi, A., Lervat, C., Entz-Werle, N., Casanova, M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00387-9 · Cited by 89
Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma
Gaspar, N., Hung, G.-Y., Strauss, S. J., Campbell-Hewson, Q., Dela Cruz, F. S., Glade Bender, J. L., Koh, K.-N., Whittle, S. B., Chan, G. C.-F., Gerber, N. U., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.4381 · Cited by 28
Metadata
- Authors
- Yonucu, S., Yιlmaz, D., Phipps, C., Unlu, M. B., & Kohandel, M.
- Affiliations
- Boğaziçi University (TR)
- University of Waterloo (CA)
- Venue
- PLoS Computational Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-09-18
- Volume
- 13
- Issue
- 9
- Pages
- e1005724
- ISSN
- 1553-734X (ISSN-L)
- 1553-7358
- PMC
- PMC5633204
- OpenAlex
- W2755804993
- Cited by
- 46
- References
- 72
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 4 · 2022: 11 · 2021: 8 · 2020: 6 · 2019: 6 · 2018: 3
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Update notices
- new_version (2017-10-09)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Computational Biology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- M Curie Reintegration Grant (268287)
- TUBITAK Grant (113F047)
- Topics
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- tumor angiogenesis, anti-angiogenic therapy, chemotherapy, drug delivery, interstitial fluid pressure, tumor microenvironment, vascular normalization, drug scheduling, drug extravasation, tumor growth modeling, nanoparticle drug delivery, combination therapy
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Computer Simulation, Dose-Response Relationship, Drug, Drug Therapy, Computer-Assisted, Humans, Models, Biological, Neoplasms, Neovascularization, Pathologic, Treatment Outcome, Tumor Burden
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.